Physician profile
Chandra Singh
NPI 1639158256
$2,983.78
in general payments reported to CMS, 2019-2025
26 companies · $456 in 2025
The $456 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $307 · 2021: $407 · 2022: $390 · 2023: $877 · 2024: $414 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,746.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $706.95 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $462.18 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Baxter Healthcare | $340.34 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Astrazeneca Pharmaceuticals LP | $294.13 | 2019-2025 | Breztri, Airsupra |
| Jazz Pharmaceuticals INC. | $248.17 | 2019-2025 | Xywav |
| Mylan Specialty L.P. | $176.67 | 2019-2024 | Yupelri |
| Harmony Biosciences LLC | $120.94 | 2023-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $69.42 | 2023-2025 | Dupixent |
| Insmed, INC. | $67.26 | 2022-2025 | Arikayce |
| Astellas Pharma US INC | $60.25 | 2020 | |
| Genzyme Corporation | $54.26 | 2024-2025 | |
| United Therapeutics Corporation | $43.94 | 2021-2025 | Tyvaso, Tyvaso |
| Inspire Medical Systems, INC. | $38.66 | 2024 | Inspire |
| Viatris Specialty LLC | $35.69 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $34.36 | 2023 | Sunosi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $33.14 | 2022-2023 | Airduo Digihaler |
| Actelion Pharmaceuticals US, INC. | $29.15 | 2025 | Opsumit |
| Grifols USA, LLC | $26.47 | 2025 | Prolastin-C Liquid |
| Avadel Cns Pharmaceuticals, LLC | $22.31 | 2024 | Lumryz |
| Xeris Pharmaceuticals, INC. | $19.66 | 2021 | |
| Lilly USA, LLC | $19.51 | 2025 | Zepbound |
| Mallinckrodt Hospital Products INC. | $19.49 | 2020 | |
| Philips North America LLC | $18.47 | 2023 | |
| Genentech USA, INC. | $15.57 | 2019 | |
| Covis Pharma Gmbh | $15.34 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.